

 $\checkmark$ 


Post-menopausal women with normal bone density do not need DXA more frequently than every five years.

## **Overactive Bladder Drugs – 75% Discontinuation Rate at One Year**

Drugs have limited effectiveness, with common and persistent side effects.<sup>1,2</sup> Reasons for discontinuation include:

- Did not work 46% of the time
- Side effects too troublesome 72% dry mouth/constipation and 65% increased dementia with anticholinergics<sup>12</sup>
- Myrbetriq (beta 3 agonist) HTN 11%, tachycardia and UTI
- Cost of VESIcare, Enablex, and Myrbetriq ~ \$4,500 yearly

## **Treatment and Management**



## Selective Pharmacotherapy Advantages for Certain Antidepressants in Women<sup>11</sup>

- ✓ Menopausal symptoms may improve with SSRI/SNRI therapy
- ✓ Insomnia may improve with tricyclic antidepressants (TCA's) or mirtazapine
- Migraine may improve with venlafaxine or TCA's
- ✓ HRT may have a role in peri-menopausal patients who are depressed

<sup>1</sup>Urological Association Journal, 9(9-10), 351-352. doi:10.5489/cuaj.3367 <sup>2</sup>GoodRx,Inc.(2018). *GoodRx*. Retrieved from GoodRx Web site: https://www.goodrx.com <sup>3</sup>NEJM, 374, 254-262. doi:10.1056/NEJMcp1513724 <sup>4</sup>NEJM, 364, 1728-1737. doi:10.1056/NEJMoa1010650 <sup>5</sup>Stangl, V Heart Journal, 29(6), 707-717. doi:10.1093/eurheartj/ehn047 <sup>6</sup>Circulation, 93(3), 450-456. Retrieved from <u>https://www.ncbi.nlm.nih.gov/pubmed/8565161</u> <sup>7</sup>JAMA, 307(8), 813-822. doi:10.1001/jama.2012.199 <sup>8</sup>NEJM, 375(15), 1438-1447. doi:10.1056/NEJMoa1600249 <sup>9</sup>Annals of Internal Medicine, 160(3), 145-153. doi:10.7326/M13-1217 <sup>10</sup>DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin. 2014;64(1):52–6 <sup>11</sup>Journal of Psychiatry and Neuroscience, 40(4), 219-221. doi:10.1503/jpn.150205 <sup>12</sup>JAMA Intern Med. 2019; 179(8):1084-1093